Press releases

2022/12/08 6:00PM

Quantum Genomics gives an update

→ pdf

2022/10/28 08:00AM

Quantum Genomics announces lack of significant efficacy for firibastat in their phase III study, FRESH and is redirecting to new developments

→ pdf

2022/10/26 08:00AM

Quantum Genomics Announces the Next Meeting of its Scientific and Clinical Committee

→ pdf

2022/10/06 6:00PM

Bryan Garnier and Co Initiates the Coverage of Quantum Genomics with a Target Price at 13 EUR per Share

→ pdf

2022/10/05 6:00PM

Quantum Genomics Publishes its 2022 First Half Results and Reviews its Activity

→ pdf

2022/09/19 07:30AM

Quantum Genomics announces that it will present the results from its phase III FRESH study on difficult-to-treat and resistant hypertension at the annual American Heart Association (AHA) conference on November 4 , 2022

→ pdf

2022/06/27 6:00PM

Quantum Genomics announces the appointment of its new Scientific Advisory Board

→ pdf

2022/05/09 6:00PM

Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESH

→ pdf

2022/05/04 6:00PM

Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs

→ pdf

2022/04/28 6:00PM

Quantum Genomics publishes its results for fiscal 2021 and gives an update on its activity

→ pdf

2022/04/27 08:45AM

Quantum Genomics announces successful capital raising with a gross sum of approximately EUR 15.6 M EUR

→ pdf

2022/04/26 5:35PM

Quantum Genomics Raises a Gross Amount of Approximately EUR 15 M

→ pdf

2022/03/31 6:00PM

Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606

→ pdf

2022/03/28 6:00PM

Quantum Genomics Announces Granting of New Patents Protecting QGC606

→ pdf

2022/03/14 6:00PM

Stéphane Cohen joins Quantum Genomics as Director of Global Operations

→ pdf

Each PDF has been scanned by antimalware and incorporates a SECURITY MASTER Footprint. To check its authenticity:
www.security-master-footprint.com